| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$10,140 |
2026 Half-Year Results Market Release
|
12 Feb 2026 9:22AM |
$55.380 |
$51.890 |
fallen by
6.30%
|
|
ASX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue grew by 11.2% to $602.8 million.
- Underlying net profit after tax increased by 3.9% to $263.6 million.
- Total operating expenses increased by 20.0%.
- Focused on technology modernization and launched new products.
- Declared a fully franked interim dividend of 101.8 cents per share.
- Dividend payout ratio was 75%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$180 |
Application for quotation of securities - LOT
|
12 Feb 2026 9:21AM |
$2.220 |
$0.660 |
fallen by
70.27%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$19,368 |
CEO Interview - 1HY26
|
12 Feb 2026 9:21AM |
$169.470 |
$185.390 |
risen by
9.39%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- 30% growth in underlying profit after tax.
- Seven new sales totaling $280 million.
- Investment in 4D Medical showed substantial gains.
- Focus on organic growth over M&A.
- Utilizing cash reserves for business investment.
- AI seen as a tool, not a disruptor.
- Expansion in cardiology offerings.
- Strategic contract with University Hospital Heidelberg.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$10,140 |
Dividend/Distribution - ASX
|
12 Feb 2026 9:21AM |
$55.380 |
$51.890 |
fallen by
6.30%
|
|
| ASX Limited (ASX) ORDINARY FULLY PAID |
Financials |
$10,140 |
Appendix 4D and 2026 Half-Year Financial Statements
|
12 Feb 2026 9:20AM |
$55.380 |
$51.890 |
fallen by
6.30%
|
|
ASX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net assets increased to $3,904.8 million by 31 December 2025.
- Operating revenue for the half-year was $602.8 million, up 11.2%.
- Statutory net profit after tax was $263.6 million.
- Earnings per share increased to 135.7 cents.
- Operating expenses, excluding significant items, totaled $247.0 million.
- Decrease in cash and financial assets by 12.1%.
- Significant changes in right-of-use assets and lease liabilities due to new lease arrangements.
- Total equity increased slightly with higher retained earnings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carnaby Resources Limited (CNB) ORDINARY FULLY PAID |
Materials |
$163 |
Shallow High Grade Results Bolster Trek 1 - 7m @ 8.9% CuEq
|
12 Feb 2026 9:20AM |
$0.470 |
$0.590 |
risen by
25.53%
|
|
CNB - Price-sensitive ASX Announcement
Full Release
Key Points
- Shallow high-grade drill results bolster development potential at Trek 1.
- Key result includes 7m at 8.9% CuEq from 35m.
- Historical underground mining at Trek 1 from 1911-1945.
- Carnaby is conducting a pre-feasibility study for open-pit mining.
- Further drilling and assessments are underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$19,368 |
Company Announcement - Interim Results
|
12 Feb 2026 9:19AM |
$169.470 |
$185.390 |
risen by
9.39%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 28.4% to $124.8 million.
- Underlying profit before tax rose by 29.7% to $90.7 million.
- Reported net profit after tax surged by 230.9% to $171.2 million.
- Unrealised gains from 4D Medical Limited investment included.
- Cash and financial assets grew to $221.8 million.
- The company remains debt-free.
- Declared fully franked interim dividend of 32 cents per share.
- Secured seven new contracts totaling over $280 million.
- New contracts include offerings in cardiology and Visage 7 products.
- Continued focus on cloud-based implementations and market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Resources Australia Ltd (AR1) ORDINARY FULLY PAID |
Materials |
$177 |
Additional Copper Unlocked via Heap Leach Remine Technology
|
12 Feb 2026 9:17AM |
$0.115 |
$0.071 |
fallen by
38.26%
|
|
AR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Identification of Heap Leach Remine opportunity at Mt Kelly.
- Approximately 45kt of residual copper identified for recovery.
- Use of patented Hydro-Jex® technology with over 20 years of proven success.
- Technology allows internal heap leaching, not possible with conventional methods.
- Potential to enhance copper recovery without additional mining or restacking.
- Reduction in operational disturbance and capital intensity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$18 |
Proposed issue of securities - OSL
|
12 Feb 2026 9:17AM |
$0.700 |
$0.585 |
fallen by
16.43%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$18 |
CEO Remuneration Update
|
12 Feb 2026 9:17AM |
$0.700 |
$0.585 |
fallen by
16.43%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSil Medical Ltd announced changes to CEO remuneration to enhance executive alignment with shareholders.
- CEO Nigel Lange agreed to a 10% reduction in fixed remuneration, replacing this with shares issued at a 121% premium.
- The shares are subject to a 12-month escrow and will require shareholder approval.
- Lange's employment terms include a fixed annual remuneration of €260,000, with 10% settled in shares.
- Eligible for a short-term incentive of up to 35% and a long-term incentive of up to 35% of base salary.
- The changes aim to preserve strategic momentum while maintaining a disciplined cost structure.
- OncoSil focuses on localised treatments for unresectable locally advanced pancreatic cancer using Phosphorous-32 Microparticles.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tyro Payments Limited (TYR) ORDINARY FULLY PAID |
Financials |
$425 |
Notification of Results - H1 FY26
|
12 Feb 2026 9:17AM |
$0.970 |
$0.800 |
fallen by
17.53%
|
|
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$28 |
NTA & Portfolio Update - January 2026
|
12 Feb 2026 9:16AM |
$0.420 |
$0.380 |
fallen by
9.52%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$23 |
NTA & Portfolio Update - January 2026
|
12 Feb 2026 9:15AM |
$0.690 |
$0.505 |
fallen by
26.81%
|
|
| Elevate Uranium Ltd (EL8) ORDINARY FULLY PAID |
Energy |
$105 |
ORP: Oobagooma Acquisition Update
|
12 Feb 2026 9:15AM |
$0.380 |
$0.225 |
fallen by
40.79%
|
|
| Orpheus Uranium Limited (ORP) ORDINARY FULLY PAID |
Materials |
$31 |
Oobagooma Acquisition Update
|
12 Feb 2026 9:15AM |
$0.067 |
$0.088 |
risen by
31.34%
|
|
| Prime Financial Group Limited (PFG) ORDINARY FULLY PAID |
Financials |
$59 |
Confirmation of H1 FY26 Financial Results & Investor Webinar
|
12 Feb 2026 9:15AM |
$0.250 |
$0.220 |
fallen by
12%
|
|
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$43 |
NTA & Portfolio Update - January 2026
|
12 Feb 2026 9:15AM |
$0.390 |
$0.325 |
fallen by
16.67%
|
|
| Syrah Resources Limited (SYR) ORDINARY FULLY PAID |
Materials |
$255 |
Graphite AAM AD/CVD rates of at least 160% finalised
|
12 Feb 2026 9:14AM |
$0.235 |
$0.110 |
fallen by
53.19%
|
|
SYR - Price-sensitive ASX Announcement
Full Release
Key Points
- AD/CVD rates of at least 160% on Chinese AAM imports finalised by the US Department of Commerce
- AD/CVD measures will apply for a minimum of five years subject to final determination by the US International Trade Commission
- Syrah Technologies LLC, a subsidiary of Syrah Resources, joined the petition with the North American Graphite Alliance
- The investigation addresses graphite AAM imports from China sold at unfairly low and subsidised prices
- DOC set a final China-wide dumping margin of 102.72% and a dumping margin of 93.5% for certain exporters
- DOC also set a final subsidy rate of approximately 67% to countervail subsidies from the Chinese government
- Measures will apply to all natural and synthetic graphite AAM products and subassemblies imported from China
- If affirmed, AD/CVD measures are expected to improve Syrah’s competitive position and lead to earlier sales commencement from the Vidalia facility
- Improved demand for Vidalia AAM and Balama natural graphite as feedstock for non-integrated facilities outside China
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Objective Corporation Limited (OCL) ORDINARY FULLY PAID |
Information Technology |
$982 |
Application for quotation of securities - OCL
|
12 Feb 2026 9:13AM |
$14.390 |
$10.230 |
fallen by
28.91%
|
|
| Middle Island Resources Limited (MDI) ORDINARY FULLY PAID |
Materials |
$13 |
Large-Scale Silver-Lead-Zinc-Antimony Targets at Tisovik
|
12 Feb 2026 9:13AM |
$0.041 |
$0.013 |
fallen by
68.29%
|
|
MDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Large-scale silver, lead, zinc, and antimony anomalies identified.
- Targets extend over a 5km east-west strike length at Tisovik.
- High-grade historical lead mining in the area.
- Anomalies remain open to the north with untested prospective limestone.
- Further soil sampling and exploration scheduled for 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LCL Resources Limited (LCL) ORDINARY FULLY PAID |
Materials |
$8 |
Receipt of Further $2 million from Colombian Divestment
|
12 Feb 2026 9:12AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$137 |
Bell Potter Unearthed Conference Presentation 2026
|
12 Feb 2026 9:10AM |
$0.495 |
$0.435 |
fallen by
12.12%
|
|
| Power Minerals Limited (PNN) ORDINARY FULLY PAID |
Materials |
$46 |
RESOURCE EXPANSION PROGRAM UNDERWAY AT RINCON LITHIUM SALAR
|
12 Feb 2026 9:10AM |
$0.105 |
$0.130 |
risen by
23.81%
|
|
| Cyclopharm Limited (CYC) ORDINARY FULLY PAID |
Health Care |
$63 |
Share Purchase Plan Offer Booklet
|
12 Feb 2026 9:10AM |
$0.930 |
$0.500 |
fallen by
46.24%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$19,368 |
Half Year Accounts
|
12 Feb 2026 9:09AM |
$169.470 |
$185.390 |
risen by
9.39%
|
|